BRAF Mutation Class and Clinical Outcomes-Response

Affiliations

¹ Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Idagogo-jack@partners.org.
² Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute Hospital, Boston, Massachusetts.
³ Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

Comment

Ibiayi Dagogo-Jack et al. Clin Cancer Res. 2019.

. 2019 May 15;25(10):3189.

doi: 10.1158/1078-0432.CCR-19-0422.

¹ Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Idagogo-jack@partners.org.
² Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute Hospital, Boston, Massachusetts.
³ Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

No abstract available

Comment on

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.
Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon C, Nguyen T, Jessop NA, Iafrate AJ, Johnson BE, Lennerz JK, Shaw AT, Awad MM. Dagogo-Jack I, et al. Clin Cancer Res. 2019 Jan 1;25(1):158-165. doi: 10.1158/1078-0432.CCR-18-2062. Epub 2018 Sep 17. Clin Cancer Res. 2019. PMID: 30224342
BRAF Mutation Class and Clinical Outcomes-Letter.
Dankner M, Rose AAN. Dankner M, et al. Clin Cancer Res. 2019 May 15;25(10):3188. doi: 10.1158/1078-0432.CCR-19-0080. Clin Cancer Res. 2019. PMID: 31092612 No abstract available.